medpagetoday news

In CLL, Benefits of Exercise Go Beyond Fatigue

An analysis showed exercise has the potential to improve T-cell ratio and reduce the proportion of T-cell subsets associated with poor prognosis in patients with chronic lymphocytic leukemia.

Chronic Lymphocytic Leukemia Survival Rates: Racial Disparities in the Spotlight

In the largest study of its kind, researchers identified persistent racial disparities in chronic lymphocytic leukemia treatment and survival outcomes, with Black patients diagnosed younger and experiencing lower survival rates.

Chronic Hematological Malignancies: When the Caregivers Need Care

Patients with chronic hematological malignancies bear significant physical and emotional pain—and so do their caregivers. Sometimes the strain faced by caregivers impedes the provision of quality care.

In CLL, Using Minimal Residual Disease

Good News for Patients with Certain Hematologic Cancers

A new study of 50 years’ worth of data from 4 Scandinavian countries showed sizable gains in survival for patients diagnosed with 1 of 7 major hematological malignancies. What’s behind this positive trend?
medpagetoday news


Brian Hill, MD, PhD, of Cleveland Clinic, discusses the EVOLVE CLL early intervention trial, which may be worth considering for high-risk patients. (1:30)

Managing Shingles in CLL Patients

Lymphoma Type May Affect Response to COVID Vaccination

The subtype of lymphoma and the timing of anticancer treatment was shown to directly affect the level of seroconversion in cancer patients administered COVID vaccination.

Chronic Lymphocytic Leukemia: A Closer Look at Clonal Cell Subpopulations

A recent study, led by a team of investigators based in the U.K., took on the task of identifying proliferative and nonproliferative subpopulations of leukemic cells in chronic lymphocytic lymphoma.

In CLL, Using Intravenous Immunoglobulin


Richter’s Transformation in CLL: What are the Risk Factors?

Leukemias and Multiple Myeloma: Building Better Studies

Findings from clinical trials for drugs to treat leukemias and multiple myeloma may not accurately represent the people who are most at risk for these diseases, because of limited participation by certain populations. That’s a design flaw that needs to be addressed as soon as possible, experts say.
medpagetoday news

Molecular Testing in CLL

Should molecular testing be ordered at the time of diagnosis or at treatment initation? There's an argument for both, says Brian Hill, MD, PhD, of Cleveland Clinic. (1:33)

In CLL, Navigating a ‘Watch and Wait’ Approach

Q&A: Do CLL Patients Benefit from High-Intensity Interval Training? Resistance Training?

Duke University investigators spoke to us about the effects of high-intensity interval training and resistance training on health-related quality of life in patients with CLL.

COVID-19 Vaccinations in Patients with Hematologic Malignancies

A 3-dose schedule or a 2-dose schedule? That question was at the core of a recent study that examined the efficacy of mRNA-1273 SARS-CoV-2 vaccination in immunocompromised patients with hematologic cancers.

In CLL, Do These Biomarkers Tell a Story About Physical Fitness and Function?

Specific clinical factors, such as treatment status and disease duration, along with certain lipid and lipoprotein levels seem to be associated with physical performance and fitness levels in patients with CLL.
medpagetoday news

TP53 Gene Mutational Status Among Patients with CLL

Using next-generation sequencing, a team of investigators retrospectively studied rates of TP53 mutations among patients with chronic lymphocytic leukemia. Some of the findings suggest that detection of subclonal TP53 mutations may change treatment.

Do Statins Improve Survival in Patients with Lymphoma?

Statins don’t significantly reduce mortality from lymphoma specifically, but rather protect against death from cardiovascular complications and other causes, a new study has concluded.

Q&A: CLL Prognostic Models

Lindsey Roeker, MD, of Memorial Sloan Kettering Cancer Center, answers our questions about prognostication in chronic lymphocytic leukemia and how it may evolve to improve outcomes, not just risk prediction.

CLL and Atrial Fibrillation: The Burden on Hospitalized Patients

Atrial fibrillation (AF), a recognized complication in patients being treated for chronic lymphocytic leukemia (CLL), deserves much wider attention in the cardio-oncology community, suggest the results of a new study. Here’s why.

CLL: Tracking a Marker of Progression

Monoclonal B-cell lymphocytosis (MBL) is known to predict chronic lymphocytic leukemia risk in certain individuals. But a new study finds that relatives of patients with MBL—either low count or high count—can be at higher risk for CLL, too.

Chronic Lymphocytic Leukemia: What Families Can Tell Us

Chronic lymphocytic leukemia is the most common type of leukemia in adults, but establishing which variables drive it has been difficult. A new study looked at genetic patterns among families with CLL for answers.

Q&A With Lindsey Roeker, MD: CLL and COVID-19 vaccine

Dr. Roeker describes what is known today about the antibody response rates to COVID-19 vaccination among patients with CLL—and what remains to be learned.

medpagetoday news

CLL and NHL Linked to Certain Skin Traits

French researchers recently examined associations among pigmentary traits, sun exposure, and risk of non-Hodgkin lymphoma and chronic lymphocytic leukemia.

What is the Evolving Role of Minimal Residual Disease Assessment in CLL?

CLL Patients Show Low Response to COVID-19 Vaccine, But Does Remission Improve Immunity?

Patients with chronic lymphocytic leukemia are at greater risk of severe disease and mortality with COVID-19 infection, and a recent study shows impaired response to vaccination, particularly among patients on active treatment.

COVID-19 Vaccination Strategies in Patients with CLL (2:50)


Emerging Technologies in CLL Laboratory Testing (2:33)

medpagetoday news

Concordance of Leukemia Outcomes Among First-Degree Relatives

Swedish investigators analyzed patient data spanning more than 50 years to get a sense of how patterns of survival are affected when patients and a first-degree relative suffer from the same type of indolent lymphoid malignancy.

In CLL: The Association of Survival and Gammaglobulin Abnormalities

Researchers studied whether levels and type of Ig monoclonal gammopathy have significance in terms of survival and on clinical and biological features in chronic lymphocytic leukemia.

Hematological Malignancies and Pneumococcal Disease Risk

A population-based study from Denmark showed a higher incidence of pneumococcal disease in adults with hematological malignancies, confirming that more effort to prevent this infection is warranted.

New Challenges in Managing Richter Transformation in the Era of Novel Agents